SAFETY OF BLOOD AND PLASMA DERIVATIVES: PATHOGEN REDUCING TECHNOLOGIES

safety of blood and plasma derivatives: pathogen reducing technologies

abstract human blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood transfusion. in this article various measures and technologies that can be applied in ord...

Pathogen reduction of blood components and plasma derivatives

The pathogen safety of plasma derivative and labile blood components has been dramatically enhanced over the last 25 years through the implementation of nucleic acid testing (NAT) technologies that effectively screen out units with high virus titers. Additionally, the incorporation of pathogen inactivation (PI) and removal steps into the manufacturing processes of plasma-derived medicinal produ...

Pathogen Reduction of Plasma

pathogen reduction of plasma

0

Natural/mild assisted reproductive technologies: reducing cost and increasing safety.

Pathogen Reduction Technologies: The Best Solution for Safer Blood?

Although it is generally accepted that blood has never been safer than today, transfusion-associated side effects, particularly infective, still occur. Unlike screening strategies, pathogen reduction technologies offer a new approach to increase blood safety by actively/directly targeting possible, also emerging pathogens or donor leukocytes. Advanced technologies for cellular blood products li...